PEPT1是位于小腸刷狀緣膜的寡肽轉(zhuǎn)運(yùn)體，介導(dǎo)蛋白消化產(chǎn)物（如二肽和三肽）及類肽藥物（如β-內(nèi)酰胺類抗生素）的攝取和轉(zhuǎn)運(yùn)。營(yíng)養(yǎng)不良及代謝失調(diào)（如高蛋白飲食、禁食和糖尿?。┚梢餚EPT1基因和蛋白表達(dá)發(fā)生變化，一些臨床常見?。ㄈ鐫冃越Y(jié)腸炎、克羅恩病、短腸綜合征）也可誘導(dǎo)腸道PEPT1的表達(dá)和功能發(fā)生改變。檢索PubMed數(shù)據(jù)庫(kù)及參考互聯(lián)網(wǎng)文獻(xiàn)，并進(jìn)行分析綜述，探討不同病理狀態(tài)對(duì)PEPT1活性調(diào)節(jié)的機(jī)制，為患者的營(yíng)養(yǎng)支持及藥物治療方案提供理論依據(jù)。

The oligopeptide transporter 1 (PEPT1) is localized to the brush-border membrane and mediates the absorption and transportation of protein digestion products (i.g. dipeptides and tripeptides) and peptide-like drugs (i.g. β-lactam antibiotics). Malnutrition and metabolic disordor (such as high-protein diet, fasting, and diabetes) could induce the modulation of protein and gene expressions of PEPT1. The intestinal diseases in clinic (such as ulcerative colitis, Cohn’s disease, and short-bowel syndrome) have shown the regulation of the PEPT1 expression and functional changes in their colon. Being analyzed and reviewed by searching PubMed Internet database and reference literature, some associated mechanisms of the regulation on PEPT1 activity by various pathological state have been studied to provide the theoretical basis for the nutritional support and pharmaceutical treatment programs.